The LIMCR

The LIMCR (Laboratory for Immunological and Molecular Cancer Research), which is integrated in the Third Medical Department of the Paracelsus Medical University Hospital, opened its doors in 2005 and has its research focus on chronic lymphocytic leukemia (CLL), myelodysplastic syndromes (MDS) and acut myeloid leukemia (AML). The LIMCR maintains a close connection with the clinic to ensure maximum synergy and efficacy in cancer therapy.

 

Click here to read more

Research Groups

 Murine-Lymphoma Models

Group leader: PD Dr. Alexander Egle

“The complexity of the disease can be mimicked in the murine model. In this system we are analyzing the effect of novel therapy concepts and the communication of leukemic cells with the immune system.” More

 Tumor immunology

Group leader: Dr. Roland Geisberger

“Leukemic cells benefit from deactivating other immune cells. We study the underlying mechanisms and search for ways to reactivate the immune system to combat leukemia.” More

 Microenvironment

Group leader: Assoc. Prof. Dr. Tanja Hartmann

"Leukemia cells are strongly dependent on the lymphoid tumor microenvironment, where they receive proliferative and pro-survival signals. We are interested in how CLL cells localize adjacent to these supportive signals." More

News

Presseartikel August 2018

Unser Gesundheitssystem ist besser, als wir denken

Beitrag Univ. Prof. Dr. Richard Greil, Primar UK für Innere Medizin III der PMU

23.-24.11.2018

2. Salzburger Gastrointestinaler Cancer Summmit -

Fokus 2018: Colorectal Cancer

Arbeitsgemeinschaft Medikamentöse Tumortherapie,

Salzburg Cancer Research Institute (SCRI)

Organisation: Univ.Prof. Dr. Richard Greil, Priv.Doz. OA Dr. Lukas Weiss, PhD

Registrierung

Sheraton Grand Salzburg, Auerspergstrasse 4, 5020 Salzburg

www.sheratongrandsalzburg.com

Presseartikel Juli 2018

Salzburger Nachrichten

Den Brustkrebs gezielt therapieren

Interview mit Univ.Prof. Dr. Richard Greil, Primar UK für Innere Medizin III